ES2715556T3 - Terapia combinada con roneparstat del mieloma múltiple - Google Patents

Terapia combinada con roneparstat del mieloma múltiple Download PDF

Info

Publication number
ES2715556T3
ES2715556T3 ES16709148T ES16709148T ES2715556T3 ES 2715556 T3 ES2715556 T3 ES 2715556T3 ES 16709148 T ES16709148 T ES 16709148T ES 16709148 T ES16709148 T ES 16709148T ES 2715556 T3 ES2715556 T3 ES 2715556T3
Authority
ES
Spain
Prior art keywords
roneparstat
melphalan
use according
multiple myeloma
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16709148T
Other languages
English (en)
Spanish (es)
Inventor
Ralph D Sanderson
C Ramani Vishnu Prakash
Alessandro Noseda
Paola Barbieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadiant Biosciences SA In Liquidazione
UAB Research Foundation
Original Assignee
Leadiant Biosciences SA In Liquidazione
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadiant Biosciences SA In Liquidazione, UAB Research Foundation filed Critical Leadiant Biosciences SA In Liquidazione
Application granted granted Critical
Publication of ES2715556T3 publication Critical patent/ES2715556T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES16709148T 2015-03-06 2016-03-03 Terapia combinada con roneparstat del mieloma múltiple Active ES2715556T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129221P 2015-03-06 2015-03-06
US201562153899P 2015-04-28 2015-04-28
PCT/IB2016/051196 WO2016142814A1 (en) 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma

Publications (1)

Publication Number Publication Date
ES2715556T3 true ES2715556T3 (es) 2019-06-04

Family

ID=55521766

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16709148T Active ES2715556T3 (es) 2015-03-06 2016-03-03 Terapia combinada con roneparstat del mieloma múltiple

Country Status (16)

Country Link
US (1) US10576101B2 (enExample)
EP (2) EP3453389A1 (enExample)
JP (1) JP2018512394A (enExample)
KR (1) KR20170138405A (enExample)
CN (1) CN107645954A (enExample)
AU (1) AU2016230859A1 (enExample)
BR (1) BR112017018869A2 (enExample)
CA (1) CA2978040A1 (enExample)
DK (1) DK3265075T3 (enExample)
ES (1) ES2715556T3 (enExample)
HK (1) HK1245107A1 (enExample)
HU (1) HUE042681T2 (enExample)
MX (1) MX2017011093A (enExample)
PL (1) PL3265075T3 (enExample)
PT (1) PT3265075T (enExample)
WO (1) WO2016142814A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
EP1427427B1 (en) 2001-09-12 2011-06-08 SIGMA-TAU Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US20100009934A1 (en) 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
EP3265075B1 (en) 2018-12-12
CN107645954A (zh) 2018-01-30
PT3265075T (pt) 2019-03-25
MX2017011093A (es) 2018-02-19
KR20170138405A (ko) 2017-12-15
CA2978040A1 (en) 2016-09-15
HUE042681T2 (hu) 2019-07-29
EP3453389A1 (en) 2019-03-13
JP2018512394A (ja) 2018-05-17
WO2016142814A1 (en) 2016-09-15
HK1245107A1 (zh) 2018-08-24
US10576101B2 (en) 2020-03-03
PL3265075T3 (pl) 2020-10-05
DK3265075T3 (en) 2019-04-08
AU2016230859A1 (en) 2017-08-17
BR112017018869A2 (pt) 2018-04-17
EP3265075A1 (en) 2018-01-10
US20180050061A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
JP2022017295A (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
ES2670700T3 (es) Tratamiento de gota e hiperuricemia
ES2589302T3 (es) Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib
AU2021297716A1 (en) Combination therapy for treatment of cancer
ES2815564T3 (es) C. novyi para el tratamiento de tumores sólidos en seres humanos
ES2969532T3 (es) 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
US20250325469A1 (en) Inhibitors of atp synthase - cosmetic and therapeutic uses
ES2914781T3 (es) Composiciones para el tratamiento de la amiloidosis
BR112019009799A2 (pt) método para tratar câncer em um paciente
CN105813637A (zh) 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
ES2826386T3 (es) Antagonistas del receptor 5HT6 para uso en el tratamiento de la enfermedad de Alzheimer con apatía como comorbilidad
ES2715556T3 (es) Terapia combinada con roneparstat del mieloma múltiple
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
US20240197904A1 (en) Combination therapy for treating glioblastoma
ES2651537T3 (es) Tratamiento y prevención de la enfermedad de Alzheimer (AD)
US20230040125A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
JP7504106B2 (ja) がんの処置のための組合せ物
ES3017257T3 (en) Abt-751 and ionizing radiation for use in treating a brain tumor
ES2848845T3 (es) Inhibidor de recidivas y/o metástasis postoperatorias del cáncer
ES2688464T3 (es) Combinación de un inhibidor de la quinasa PI3 con paclitaxel para su uso en el tratamiento o la prevención de un cáncer de cabeza y cuello
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
WO2022016231A1 (en) Methods of treatment
Nicholas et al. Trials of Novel Therapies Specifically for Progressive MS